Symbiotec Pharmalab Day 2: GMP at ₹350 (35.43%) & 1.95x Subscribed
Key takeaways:
- Symbiotec Pharmalab IPO is a book-built issue of ₹1,757 crore, which includes a fresh issue of ₹150 crore and an OFS of ₹1,607 crore.
- At the end of day 2, the issue has an overall subscription of 1.95 times. Retail Individual Investors (RIIs) subscribed 2.22 times.
- In the unlisted market, sentiment is highly bullish, with the GMP at ₹350, pointing to a potential listing premium of 35.43%.
- The company has a massive portfolio of more than 60 APIs, backed by US FDA- and WHO GMP-certified manufacturing plants in Madhya Pradesh.
Symbiotec Pharmalab Ltd IPO received a massive response from investors on the second day of bidding for its initial public offering (IPO). It is a global leader in the manufacturing of corticosteroid and steroid hormone active pharmaceutical ingredients (APIs). On Day 2, the IPO achieved an overall subscription of 1.95 times and a GMP of ₹350.
The IPO is a book-built issue of ₹1,757.00 crore. This includes a fresh issue of ₹150.00 crore and an offer for sale (OFS) of ₹1,607.00 crore by the existing promoters and shareholders. The proceeds from the fresh issue will be used to repay or prepay outstanding borrowings and for general corporate purposes.
With its strong positioning in the global API market, the offering has commanded a positive reception from retail and non-institutional participants. Let's explore in detail what transpired on day 2 of Symbiotec Pharmalab IPO.
Key dates of Symbiotec Pharmalab IPO
The Symbiotec Pharmalab IPO opened for subscription on Monday, August 24, 2026. Investors can place their bids until the issue closes on Thursday, August 27, 2026. The IPO allotment is expected to be finalised on Friday, August 28, 2026.
If an investor does not get an allotment, the refund process will begin on Monday, August 31, 2026, along with the direct credit of the allotted shares to the demat accounts of successful bidders. The company's equity shares are likely to be listed on Bombay Stock Exchange (BSE) and National Stock Exchange (NSE) on Tuesday, September 1, 2026.
The price band of the issue is set at ₹938 to ₹988 per share. Retail investors will be allowed to buy a minimum of 1 lot of 15 shares, which will cost them a minimum of ₹14,820 at the upper price range. MUFG Intime India Pvt. Ltd. is the issue's registrant, while JM Financial Ltd. is the book-running lead manager.
About Symbiotec Pharmalab
Incorporated in 2002, Symbiotec Pharmalab Ltd has become a global heavyweight in the biopharmaceutical and biotechnological manufacturing space. The company is engaged in the development and manufacturing of complex active pharmaceutical ingredients (APIs) primarily in the field of corticosteroids and steroidal hormones.
These facilities are certified by global regulatory bodies such as the US FDA, EU GMP and WHO GMP. Symbiotec also holds 42 Drug Master Files (DMFs) with the US FDA and 23 CEPs with the EDQM, which further strengthens its export business model.
The company has had stable financial growth in recent years. In FY26, Symbiotec Pharmalab posted total income of ₹872.26 crore, a healthy EBITDA margin of approximately 26.59%, and profit after tax (PAT) of ₹109.90 crore.
Recent GMP and subscription status on Day 2
At the end of Day 2 bidding (August 25, 2026), the Symbiotec Pharmalab IPO witnessed a healthy uptick in demand, with the issue being subscribed 1.95 times. The Non-Institutional Investors (NII) segment was booked 3.16 times.
Retail Individual Investors (RIIs) subscribed their share by 2.22 times. The employee-reserved portion received an aggressive bid, at 3.19 times. As usual, Qualified Institutional Buyers (QIBs) showed a measured response, subscribing 0.57 times their quota, with bulk bids expected on the last day.
Sentiment in the unlisted grey market remains positive for this IPO. The current Grey Market Premium (GMP) of Symbiotec Pharmalab is ₹350. This suggests a potential listing price of ₹1,338 per share, representing a potential listing gain of 35.43% at the upper price band of ₹988.
What is next?
Day 2 subscription growth is driven by Symbiotec Pharmalab's global leadership in a highly specialised, high-barrier API segment. It also has a strong fundamental foundation, with strict regulatory approvals in key international markets and consistent operating margins.
However, investors are still cautious due to several regulatory risks in the pharma industry, the company's pending tax and civil litigation, and its heavy dependence on raw material imports.
As the IPO heads toward its closing date on August 27, all eyes will be on the Qualified Institutional Buyers (QIB) segment. A strong institutional push on the final day will likely help sustain the elevated grey market premium and set the stage for a strong market debut on September 1.
